Akamine Scott 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Dec 7, 2023
Insider Transaction Report
Form 4
Akamine Scott
Chief Legal Officer
Transactions
- Sale
Common Stock
2023-12-05$35.00/sh−7,500$262,500→ 513 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-05−7,500→ 264,262 totalExercise: $13.17Exp: 2031-06-01→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2023-12-05$13.17/sh+7,500$98,775→ 8,013 total - Sale
Common Stock
2023-12-07$41.37/sh−10,000$413,700→ 513 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-07−10,000→ 254,262 totalExercise: $13.17Exp: 2031-06-01→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2023-12-07$13.17/sh+10,000$131,700→ 10,513 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
- [F2]Includes 513 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
- [F3]25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.